Specifically, galectin-3 increased expression is reported in active injured regions in MS patients [122], and in postmortem MS human brain tissues [123], thereby appearing to be an important therapeutic target in neurodegenerative disorders including MS [124]. Here, LGALS3 is linked to myeloid sarcoma.